Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Randomized Controlled Trial of Mind-Body Breathing Therapy (in Chronic Obstructive Pulmonary Disease) To Improve Palliation of Dyspnea and Health-Related Quality of Life
Dyspnea (shortness of breath) is a complex experience that includes interpretation of
physical impairments and associated distress to the person. The role of mind-body
interactions in the experience of the symptom of dyspnea suggests that complementary and
alternative medicine (CAM) therapies may be effective in abating dyspnea and improving
patients' health-related quality of life. CAM strategies work in a number of ways that are
directly applicable to dyspnea, such as decreasing the stress response, inducing relaxation,
and facilitating a less distressful interpreted experience of physical disorders.
We have combined a number of established CAM approaches aimed at breath-centered mindfulness
and relaxation into an single therapy, mind-body breathing therapy (MBBT). The purpose of
this study is to test the efficacy of MBBT in improving dyspnea and health-related quality
of life for patients with emphysema (chronic obstructive pulmonary disease).
Objectives We aim to test the feasibility and efficacy of mind-body breathing therapy (MBBT)
in improving dyspnea and health-related quality of life for patients suffering from
late-stage COPD. This randomized controlled trial seeks to assimilate a number of
complementary and alternative (CAM) approaches aimed at breath-centered symptom abatement
and relaxation into an single therapy and test its efficacy as a palliative care
intervention.
Research Plan Patients will be enrolled from outpatient clinics, primarily pulmonary
medicine (COPD patients), at the Veteran Affairs (VA) Greater Los Angeles Healthcare System.
Patients will be randomized to intervention or control arms. Each arm will include a weekly
meeting on the VA campus for 8 successive weeks. Evaluation will include pre/post
measurements, serial self-report data, compliance measures, chart abstracted objective data,
and follow-up evaluations for 2 months following the intervention or until death. Grant and
project will begin in October 2005 and run for one year.
Methods The overall design is a randomized controlled trial of the MBBT intervention on
dyspnea symptoms and health-related quality of life (HRQOL). The study will aim to enroll
120 patients over a one year period. We will enroll cognitively intact patients with
advanced COPD and dyspnea. Potential subjects will be identified by flyers or provider
invitation; screening will ask about enrollment criteria and verified after consent through
medical record. Subjects will be recruited through physicians though public advertising and
recruitment within the VA will be used to inform patients and physicians of the trial.
Patients will be screened at intake during vital signs and offered participation when
identified with dyspnea of at least 4 out of 10 points on the Borg Dyspnea Scale. Patients
randomized to intervention arm will attend a 8-week session on MBBT that will include a 15
minute video designed by Jon Kabat-Zinn for dyspnea, a relaxation response pocket-guide with
group practice and a daily prescription for practice, and weekly mind-body guided sessions
for controlled breathing. Control patients will be invited to attend an 8-week session
consisting of the a support group with equivalent time and attention as well as identical
measures.
Results Primary study outcomes are patients' self report of the severity of dyspnea and
HRQOL. Baseline dyspnea will be quantified with the Baseline Dyspnea Index and Borg scale
with regular measures of dyspnea using the Visual Analog Scale (VAS). Functional limitation
will be measured by the 6-minute walk test and followed with the baseline measure of
post-exercise dyspnea level on the Borg scale. Other symptoms will be identified by the
Memorial Symptom Assessment Scale (MSAS) and as part of the Saint George Respiratory
Questionnaire (SGRQ). HRQOL will be measured by the SGRQ, a 76-item self-administered
questionnaire measuring 3 domains (symptoms, activity, and impact of disease on daily life),
and in a more general way by the physical health score and mental health score of the
Veterans RAND 36 Item Health Survey (VR-36).
Clinical Significance Chronic obstructive pulmonary disease (COPD) is the fourth leading
cause of death with increasing prevalence throughout the world and within the VA. Dyspnea is
among the most troublesome symptoms these patients experience. Mindfulness based meditative
strategies has been shown to improve functioning and quality of life, and palliate pain in
other populations. However, no trial has specifically evaluated mindful practices or
mind-body breathing techniques in the palliation of dyspnea. If shown to be effective, MBBT
may represent an important palliative strategy in the management of conditions prevalent in
the Veteran population and in medical care in general.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|